ZIVO Bioscience Statistics
Share Statistics
ZIVO Bioscience has 64.00M shares outstanding. The number of shares has increased by 42.13% in one year.
| Shares Outstanding | 64.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.30M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -0.26 and the forward PE ratio is null.
| PE Ratio | -0.26 |
| Forward PE | null |
| PS Ratio | 73.35 |
| Forward PS | null |
| PB Ratio | -0.92 |
| P/FCF Ratio | -0.35 |
| PEG Ratio | n/a |
Enterprise Valuation
ZIVO Bioscience Inc. has an Enterprise Value (EV) of 2.16M.
| EV / Earnings | -0.28 |
| EV / Sales | 77.94 |
| EV / EBITDA | -0.3 |
| EV / EBIT | -0.3 |
| EV / FCF | -0.37 |
Financial Position
The company has a current ratio of 0.15, with a Debt / Equity ratio of -0.11.
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Debt / Equity | -0.11 |
| Total Debt / Capitalization | -12.21 |
| Cash Flow / Debt | -24.17 |
| Interest Coverage | -14.13 |
Financial Efficiency
Return on equity (ROE) is 3.53% and return on capital (ROIC) is 390.59%.
| Return on Equity (ROE) | 3.53% |
| Return on Assets (ROA) | -13.99% |
| Return on Capital (ROIC) | 390.59% |
| Revenue Per Employee | 3.46K |
| Profits Per Employee | -972.15K |
| Employee Count | 8 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.26, so ZIVO Bioscience 's price volatility has been higher than the market average.
| Beta | 0.26 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.51 |
| Relative Strength Index (RSI) | 61.63 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, ZIVO Bioscience had revenue of $27.65K and earned -$7.78M in profits. Earnings per share was $-4.6.
| Revenue | 27.65K |
| Gross Profit | 11.61K |
| Operating Income | -7.26M |
| Net Income | -7.78M |
| EBITDA | -7.26M |
| EBIT | -7.26M |
| Earnings Per Share (EPS) | -4.6 |
Balance Sheet
The company has $274.38K in cash and $346.34K in debt, giving a net cash position of -$71.96K.
| Cash & Cash Equivalents | 274.38K |
| Total Debt | 346.34K |
| Net Cash | -71.96K |
| Retained Earnings | -123.58M |
| Total Assets | 495.59K |
| Working Capital | -2.14M |
Cash Flow
In the last 12 months, operating cash flow was -$5.80M and capital expenditures $0, giving a free cash flow of -$5.80M.
| Operating Cash Flow | -5.80M |
| Capital Expenditures | 0 |
| Free Cash Flow | -5.80M |
| FCF Per Share | -3.43 |
Margins
Gross margin is 41.99%, with operating and profit margins of -26.27K% and -28.13K%.
| Gross Margin | 41.99% |
| Operating Margin | -26.27K% |
| Pretax Margin | -28.13K% |
| Profit Margin | -28.13K% |
| EBITDA Margin | -26.27K% |
| EBIT Margin | -26.27K% |
| FCF Margin | -20.98K% |
Dividends & Yields
ZIVOW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ZIVOW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -468.99 |
| Piotroski F-Score | 2 |